Koroukian Siran M, Bakaki Paul M, Schluchter Mark D, Owusu Cynthia
Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, Ohio.
J Geriatr Oncol. 2011 Jul;2(3):200-208. doi: 10.1016/j.jgo.2011.02.004.
To examine the effects of the occurrence and co-occurrence of comorbidities (COM), functional limitations (FL), and geriatric syndromes (GS) on treatment and outcomes in older cancer patients. MATERIALS AND METHODS: We used records from the Ohio Cancer Incidence Surveillance System linked with Medicare data, clinical assessment data from the home health care Outcomes and Assessment Information Set, and death certificate data. Our patient population included fee-for-service HHC Medicare beneficiaries diagnosed with incident loco-regional breast or colorectal cancer in years 1999-2001 (n=1236). We grouped patients according to the presence of multimorbidity: (0): none of COM, FL, or GS; (1): occurrence - but no co-occurrence - of COM, FL, or GS; (2): co-occurrence of any two of COM, FL, and GS; and (3): co-occurrence of all three of COM, FL, and GS. Our outcomes were receipt of standard treatment, as well as overall survival (OS) and disease-specific survival (DSS) through 2005. Multivariable regression models were developed to analyze the independent association between multimorbidity and the outcomes, before and after adjusting for age. RESULTS: The effect of multimorbidity on our outcomes was attenuated considerably by age. Adjusting for age and compared with no multimorbidity (0), high multimorbidity (3) remained significantly and negatively associated with receipt of standard treatment (adjusted odds ratio: 0.57, 95% Confidence Interval (CI): 0.33, 0.97). Furthermore, high multimorbidity (3) was associated with increased hazard for OS, but not for DSS (adjusted hazard ratio and 95% CI: 2.15 (1.58, 2.93) for three entities). CONCLUSION: Multimorbidity is significantly and independently associated with cancer treatment and OS, but not DSS.
研究共病(COM)、功能受限(FL)和老年综合征(GS)的发生及共现对老年癌症患者治疗及预后的影响。材料与方法:我们使用了俄亥俄州癌症发病率监测系统的记录,并将其与医疗保险数据、家庭医疗保健结果与评估信息集的临床评估数据以及死亡证明数据相链接。我们的患者群体包括1999 - 2001年诊断为局部区域性乳腺癌或结直肠癌的按服务收费的家庭医疗保健医疗保险受益人(n = 1236)。我们根据多种疾病的存在情况对患者进行分组:(0):无COM、FL或GS;(1):COM、FL或GS出现但无共现;(2):COM、FL和GS中任意两者共现;(3):COM、FL和GS三者共现。我们的结局指标包括是否接受标准治疗,以及截至2005年的总生存期(OS)和疾病特异性生存期(DSS)。建立多变量回归模型以分析多种疾病与结局之间在调整年龄前后的独立关联。结果:多种疾病对我们结局的影响在很大程度上因年龄而减弱。调整年龄后,与无多种疾病(0)相比,高多种疾病(3)与接受标准治疗仍存在显著负相关(调整后的优势比:0.57,95%置信区间(CI):[0.33, 0.97])。此外,高多种疾病(3)与OS风险增加相关,但与DSS无关(三种情况的调整后风险比及95% CI:2.15(1.58, 2.93))。结论:多种疾病与癌症治疗及OS显著且独立相关,但与DSS无关。